Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma

In conclusion, the optimal Treg depleting dose and schedule of CTX, when combined with everolimus, is 50 mg once daily. This combination leads to acceptable adverse events in comparison with everolimus alone. Currently, the here selected combin ation is being evaluated in a phase II clinical trial.Trial registrationNCT01462214. (Source: Cancer Immunology, Immunotherapy)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2PR8w6o